By Julie Steenhuysen and Sharon Begley CHICAGO/NEW YORK (Reuters) – With hundreds of patients in Africa suffering the devastating effects of Ebola, health experts are scrambling to determine which drugs might offer the best experimental treatment, and researchers are being pressed by government officials to speed up their work. One, produced by tiny California biotech Mapp Biopharmaceutical, gained international prominence this week when it was given to two U.S. aid workers who contracted Ebola in West Africa and have since shown signs of improvement. Others are from Vancouver-based Tekmira Pharmaceuticals and privately-held Profectus BioSciences, of Tarrytown, NY. U.S. drugmakers are fielding questions from government officials about their ability to supply treatments in sufficient quantities should the request come.
Please Like Us!!!